绥美凯在中国上市了吗？

Is it listed in China? In 2015, Suimeikai submitted a clinical application in China; on January 20, 2017, it applied for import and received priority review status; on August 1, 2017, the State Food and Drug Administration (CFDA) approved Suimeikan, a new compound preparation for AIDS treatment, to enter China.

Suimeikai is a compound preparation. Each tablet contains dolutegravir sodium (calculated as dolutegravir) 50mg, abacavir sulfate (calculated as abacavir) 600mg and lamivudine 300mg. Clinically, it is suitable for the treatment of adults infected with human immunodeficiency virus (HIV) and adolescents over 12 years old (with a minimum weight of 40kg). Clinically, it is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B5701 allele, he should not take products containing abacavir.

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted into the active metabolite carbavir triphosphate (CBV-TP), a deoxyguanosine-5'-triphosphate (dGTP) analogue, under the action of intracellular enzymes. CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate dGTP and inserting into viral DNA. Lamivudine is a synthetic nucleoside analogue. Lamivudine is phosphorylated in cells to generate the active 5-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The main mode of action of 3T-CTP is to terminate DNA chain synthesis by inserting nucleotide analogs, thereby inhibiting RT activity.

The recommended dosage is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.